[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574781":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":58,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":87,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Genotype-guided abbreviated DAPT","ACTIVE_COMPARATOR","Rapid (CYP2C19\\*1\u002F\\*17 or \\*17\u002F\\*17) or normal metabolizers (CYP2C19\\*1\u002F\\*1) for clopidogrel will receive clopidogrel monotherapy and intermediate or poor metabolizers will receive potent P2Y12 inhibitor (prasugrel or ticagrelor) monotherapy (patients carrying a CYP2C19\\*2 or \\*3 alleles) after 1 month of potent P2Y12 inhibitor based DAPT.",[13],"Drug: P2Y12 antagonist monotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Un-guided de-escalation of DAPT","A potent P2Y12 inhibitor is changed to clopidogrel 1 month after PCI, and aspirin is maintained.",[18],"Drug: clopidogrel + aspirin",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","P2Y12 antagonist monotherapy","CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\\*1\u002F\\*17 or \\*17\u002F\\*17) or normal (CYP2C19\\*1\u002F\\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\\*2 or \\*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"clopidogrel + aspirin","In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).",[15],[31],{"name":32,"affiliation":5,"role":33},"Joo-Yong Hahn, MD, PhD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","82-2-3410-3419","jyhahn@skku.edu",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Ki Hong Choi, MD, PhD","82-2-3410-6653","cardiokh@gmail.com",[44],{"facility":5,"status":25,"city":45,"state":25,"zip":46,"country":47,"countryCode":25,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Seoul","06351","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55,56],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":57,"role":36,"phone":41,"phoneExt":25,"email":42},"Ki Hong Choi",{"type":33,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Joo-Yong Hahn","Professor","100574781","phase-4-genotype-guided-abbreviated-dapt-versus-un-guided-de-escalation-therapy-in-patients-with-acs-and-hbr-100574781",false,"NCT06763744","Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","SMart Angioplasty Research Team- Genotype-Guided Abbreviated DUal AntIplatelet Therapy Versus Un-Guided De-escalation Therapy in Patients With Acute Coronary SyndromE and High Bleeding Risk (SMART-GUIDE-HBR)","GUIDE-HBR","Inclusion Criteria:\n\n* Patients must be at least 19 years of age\n* Patients who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n* Patients presenting with ACS (ST-elevation myocardial infarction \\[STEMI\\] or non-ST-elevation \\[NSTE\\] ACS).\n* Patients with at least one lesion with equal or greater than 50% diameter stenosis requiring treatment with drug-eluting stents in native coronary artery or graft.\n* Patients with high bleeding risk (by ARC-HBR definition or PRECISE-DAPT score 25 or more)\n\nExclusion Criteria:\n\n* Patients unable to provide consent.\n* Patients who need chronic anti-coagulation therapy.\n* Patients suffering from cardiogenic shock or cardiac arrest\n* Patients with known intolerance to aspirin, all P2Y12 inhibitors, or components of drug-eluting stents.\n* Clinically significant out of range values for platelet count (\\\u003C 50,000\u002Fmm3) or hemoglobin (\\\u003C8 g\u002FdL) at screening\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment).\n* Pregnant or lactating women.","ALL","19 Years",{"count":72,"type":73},3000,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients with acute coronary syndrome (ACS) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).",[79,80],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","High Bleeding Risk",[82,83,84,85,86],"CYP2C19 Genotype","Acute coronary syndrome","De-escalation therapy","P2Y12 inhibitor monotherapy","High bleeding risk","NOT_YET_RECRUITING","2025-05-14",{"date":90,"type":91},"2025-05-18","ACTUAL",{"date":93,"type":73},"2025-06-01",{"date":95,"type":73},"2029-12-31",{"name":5,"class":6},1]